Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 13/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409093 | 1.00 | PTGS2 (0.34) | PTGS2PTGS1KDM4EALDH1A1GAA | |
| SCHEMBL6405345 | 0.91 | PTGS2 (0.42) | PTGS2PTGS1KDM4EALDH1A1GAA | |
| SCHEMBL6407729 | 0.91 | PTGS2 (0.42) | PTGS2PTGS1KDM4EALDH1A1GAA | |
| SCHEMBL6405233 | 0.86 | PTGS2 (0.39) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL6408565 | 0.86 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL6408639 | 0.86 | PTGS2 (0.39) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL6405577 | 0.86 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL6404858 | 0.84 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL6405127 | 0.84 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL6404998 | 0.84 | PTGS2 (0.48) | PTGS2PTGS1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | G.D. SEARLE & CO. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6822102-B2 | COMPOUNDS SUCH AS (2S,3R)-6,8-DICHLORO-3,4-DIHYDRO-2-(TRIFLUOROMETHYL)-2H-1-BENZOPYRAN-3 -CARBOXYLIC ACID, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC, ANTICARCINOGENIC AGENTS OR ANALGESICS | PHARMACIA CORPORATION | 2004-11-23 | — | — | US | disclosed |
| EP-1274700-B1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORP (US) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 5/4885KDM4E 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.